Patients Previously Transfused or Treated with Epoetin Alfa at Low Baseline Hemoglobin Are at Higher Risk for Subsequent Transfusion: An Integrated Analysis of the Canadian Experience

Patients Previously Transfused or Treated with Epoetin Alfa at Low Baseline Hemoglobin Are at Higher Risk for Subsequent Transfusion: An Integrated Analysis of the Canadian Experience Ian Quirt, Michael Kovacs, Félix Couture, A. Robert Turner, Michael Noble, Ronald Burkes, Sean Dolan, Richard K. Plante, Catherine Y. Lau, José Chang Oncologist 2006; 11: 73-82 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in sarcomas and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Identify chemotherapy patients at risk of transfusion by carefully monitoring hemoglobin levels and prior incidence of transfusion. Define the optimal Hb target at which epoetin alfa treatment should be initiated to minimize subsequent transfusion need. Understand that more than 85% of units transfused occurred in patients receiving epoetin alfa with baseline Hb <10g/dl and evaluate the clinical impact of early treatment initiation. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jan. 10, 2006 Most Recent Review: May 8, 2007* Most Recent Update: Jan. 10, 2006 Date Credit Expires: Jan. 10, 2008 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.